Monday, December 5, 2022
Home > BUSINESS > Vaccines Sales Pushed Pfizer Beyond The Expectations in the Final Quarter

Vaccines Sales Pushed Pfizer Beyond The Expectations in the Final Quarter

The sales of the novel corona virus vaccine has been responsible for boosting the earnings of Pfizer pretty well past the expectations of the analyst in the final quarter of the year 2021, but the drug producing company has been setting a bar that is expected for the year 2022.

On Tuesday, 8th February 2022, the company ‘Pfizer’ is now expecting the adjusted earnings in the year 2022 to range starting from 6.35 dollars to 6.55 dollars per share on the 98 billion dollars to 102 billion dollars in the revenue. The industry analysts had also been expecting the earnings of 6.71 dollars per share on the 103.18 billion dollars in the revenue.

In the fourth quarter of the year 2021, the company said that, the two-dose novel corona virus vaccine has been responsible in bringing more than 12.5 billion dollars in the revenue that has been helping the total top line of the company, which has been double as compared to the last quarter of the year 2020.

The company ‘Pfizer’ has been booking the large majority of the revenue from the splits profit and also the cost for making and distributing the novel corona virus vaccine along with the development partner of the company ‘BioNTech’.

Later in the fourth quarter of 2021, the company has also launched Paxlovid, which has been the first covid-19 treatment pill for fighting the corona virus disease, and this new drug has also generated around 76 million dollars in the sales of the country after receiving the approval of the US regulatory.